J&J Said to Agree to $2.2 Billion Drug Marketing Accord

Johnson & Johnson agreed to pay as much as $2.2 billion to settle U.S. probes of the marketing of its Risperdal antipsychotic drug and other medications, two people familiar with the negotiations said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.